This technology presents a computationally evolved peptide therapeutic that targets human lysine tRNA to disrupt the HIV-1 replication cycle.
Background: HIV-1 replication poses a significant challenge for therapeutic intervention due to the virus’s complex interaction with host cellular mechanisms. Existing treatments often face limitations such as drug resistance and toxicity. To address this, researchers sought to develop a novel peptide-based inhibitor capable of specifically binding to RNA structures essential for viral replication, offering a targeted approach to impede HIV-1’s lifecycle.
Technology Overview: The invention utilizes advanced computational techniques to design and optimize an amino acid peptide. This peptide is engineered to bind with high affinity and specificity to the anticodon stem and loop region of human lysine tRNA, a critical component involved in the HIV-1 replication process. By targeting this RNA structure, the peptide interferes with protein functions necessary for viral propagation. The design was performed in silico to predict sequences that demonstrate optimal binding properties. Following computational optimization, the peptide’s binding efficacy was confirmed experimentally using fluorescence assays. This integrated approach not only accelerates the discovery of RNA-binding peptides but also enhances their specificity and effectiveness compared to traditional methods. The novelty of this technology lies in its combination of computational modeling and experimental validation to generate a targeted therapeutic agent. This method can be extended to develop peptides for various RNA targets, broadening its potential utility beyond HIV to other diseases where RNA interactions play a pivotal role.
https://suny.technologypublisher.com/files/sites/adobestock_607532147.jpeg
Advantages: • High specificity and affinity for human lysine tRNA, minimizing off-target effects. • Computational design accelerates development and optimizes peptide properties before synthesis. • Potential to disrupt HIV-1 replication without traditional antiviral drugs, offering a new therapeutic pathway. • Versatile platform applicable to designing peptides against different RNA targets in various diseases. • Validated through fluorescence assays, ensuring reliability of computational predictions.
Applications: • Development of novel HIV-1 therapeutics aimed at inhibiting viral replication. • Research tool in molecular and cellular biology to study RNA-protein interactions. • Potential platform for creating peptide-based treatments targeting RNA structures in other viral infections or diseases. • Biochemical applications where selective RNA-binding peptides are required to modulate cellular processes. • Licensing opportunities for pharmaceutical companies interested in innovative antiviral agents.
Intellectual Property Summary: Issued patent 9,975,922
Stage of Development: TRL 4
Licensing Status: This technology is available for licensing.